Thurston, Springer, Miller, Herd & Titak, Inc. Crispr Therapeutics Ag Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $283 Million
- Q2 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 1,346 shares of CRSP stock, worth $74,070. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,346Holding current value
$74,070% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
551Shares Held
56.3MCall Options Held
2.91MPut Options Held
2.47M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.16MShares$449 Million3.97% of portfolio
-
Capital International Investors Los Angeles, CA7.84MShares$431 Million0.11% of portfolio
-
Nikko Asset Management Americas, Inc.3.27MShares$180 Million2.23% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.27MShares$180 Million0.16% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.7MShares$149 Million0.11% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.29B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....